Anthony C Keech

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. ncbi request reprint Interpreting the results of a clinical trial
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 186:318-9. 2007
  2. ncbi request reprint Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney NSW 2006, Australia
    Diabet Med 22:1558-65. 2005
  3. ncbi request reprint Balancing the outcomes: reporting adverse events
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 181:215-8. 2004
  4. ncbi request reprint Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
  5. doi request reprint Cost-effectiveness considerations of cardiovascular therapeutics
    Anthony Keech
    NHMRC Clinical Trials Centre and Department of Cardiology, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
    Heart Lung Circ 18:118-22. 2009
  6. doi request reprint Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Andrew Tonkin
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Am Heart J 163:508-14. 2012
  7. pmc Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial
    Russell Scott
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cardiovasc Diabetol 10:102. 2011
  8. pmc Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
    Kushwin Rajamani
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Lancet 373:1780-8. 2009
  9. doi request reprint HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes
    Boris Waldman
    NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney, Sydney, Australia
    Diabetes Care 37:2351-8. 2014
  10. doi request reprint The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, NSW, Australia
    Diabetologia 58:464-73. 2015

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Interpreting the results of a clinical trial
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 186:318-9. 2007
  2. ncbi request reprint Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney NSW 2006, Australia
    Diabet Med 22:1558-65. 2005
    ..The objective of this study was to identify the determinants of carotid intima media thickness (IMT) in patients with Type 2 diabetes...
  3. ncbi request reprint Balancing the outcomes: reporting adverse events
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 181:215-8. 2004
  4. ncbi request reprint Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
    ..Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus...
  5. doi request reprint Cost-effectiveness considerations of cardiovascular therapeutics
    Anthony Keech
    NHMRC Clinical Trials Centre and Department of Cardiology, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
    Heart Lung Circ 18:118-22. 2009
    ....
  6. doi request reprint Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Andrew Tonkin
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Am Heart J 163:508-14. 2012
    ..In the FIELD study, comparison of the effect of fenofibrate on cardiovascular disease (CVD) between those with prior CVD and without was a prespecified subgroup analysis...
  7. pmc Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial
    Russell Scott
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cardiovasc Diabetol 10:102. 2011
    ....
  8. pmc Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
    Kushwin Rajamani
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Lancet 373:1780-8. 2009
    ..Our aim was to assess the effect of fenofibrate on amputation events in a large cohort of patients with type 2 diabetes...
  9. doi request reprint HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes
    Boris Waldman
    NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney, Sydney, Australia
    Diabetes Care 37:2351-8. 2014
    ..We evaluated associations of HDL-C, apolipoprotein A-I (apoA-I), and HDL-C/apoA-I with insulin secretion, insulin resistance, HbA1c, and long-term glycemic deterioration, reflected by initiation of pharmacologic glucose control...
  10. doi request reprint The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, NSW, Australia
    Diabetologia 58:464-73. 2015
    ..This study investigated the relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 diabetes...
  11. doi request reprint Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes
    Philip M Clarke
    School of Public Health, University of Sydney, Sydney, New South Wales
    Med Care 47:61-8. 2009
    ....
  12. pmc Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort
    James D Best
    Department of Medicine, University of Melbourne Medical School, St Vincent s Hospital, Melbourne, Victoria, Australia
    Diabetes Care 35:1165-70. 2012
    ..We assessed the adequacy of metformin, sulfonylureas, and insulin to maintain glycemic control and their effects on weight...
  13. ncbi request reprint Putting results of a clinical trial into perspective
    Nicholas R Wilcken
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Med J Aust 186:368-70. 2007
  14. doi request reprint Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes
    Markus Herrmann
    Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, Australia
    Diabetes Care 38:521-8. 2015
    ..People with diabetes frequently develop vascular disease. We investigated the relationship between blood 25-hydroxyvitamin D (25OH-D) concentration and vascular disease risk in type 2 diabetes...
  15. ncbi request reprint Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
    Markus Herrmann
    Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, Australia
    Clin Chem Lab Med 50:2213-9. 2012
    ..This study investigated the relationship between HCY and the risk of VTE in patients treated with fenofibrate...
  16. doi request reprint Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    David C Burgess
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Eur Heart J 31:92-9. 2010
    ....
  17. ncbi request reprint Subgroup analysis in clinical trials
    David I Cook
    Department of Physiology F 13, University of Sydney, Sydney, NSW 2006, Australia
    Med J Aust 180:289-91. 2004
  18. pmc Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study
    Ru Dee Ting
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
    Diabetes Care 35:218-25. 2012
    ..We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study...
  19. ncbi request reprint Subgroup analysis: application to individual patient decisions
    R John Simes
    NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW 2050, Australia
    Med J Aust 180:467-9. 2004
  20. pmc An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes
    Jonathan E Noonan
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia
    Diabetes 62:3968-75. 2013
    ..Its incorporation into clinical practice should be continually revised as more information becomes available. ..
  21. ncbi request reprint Multiple analyses in clinical trials: sound science or data dredging?
    Sarah J Lord
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 181:452-4. 2004
  22. doi request reprint Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy
    Jason A Harmer
    Sydney Medical School, University of Sydney, Sydney, NSW, Australia Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia Electronic address
    Diabetes Res Clin Pract 106:328-36. 2014
    ..We investigated factors associated with impaired arterial function in adults with type 2 diabetes...
  23. doi request reprint Balloon warming time is the strongest predictor of late pulmonary vein electrical reconnection following cryoballoon ablation for atrial fibrillation
    Justin Ghosh
    Royal Prince Alfred Hospital, Sydney, Australia
    Heart Rhythm 10:1311-7. 2013
    ..Pulmonary vein isolation by cryoballoon ablation is an accepted method of treating atrial fibrillation. Little data exist regarding factors affecting late electrical reconnection of pulmonary veins following cryoballoon ablation...
  24. doi request reprint Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial
    Rebecca Dignan
    Liverpool Hospital, University of New South Wales, Sydney, NSW, Australia Electronic address
    Int J Cardiol 168:5378-84. 2013
    ....
  25. doi request reprint Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2042, Australia
    J Clin Endocrinol Metab 97:4701-8. 2012
    ....
  26. ncbi request reprint Flow of participants in randomised studies
    Burcu Cakir
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 178:347-9. 2003
  27. ncbi request reprint Recruitment to randomised studies
    Wendy E Hague
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
    Med J Aust 178:579-81. 2003
  28. ncbi request reprint Statistical methods in clinical trials
    Val J Gebski
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450
    Med J Aust 178:182-4. 2003
  29. ncbi request reprint Inclusion of patients in clinical trial analysis: the intention-to-treat principle
    Stephane R Heritier
    NHMRC Clinical Trial Centre, University of Sydney, Camperdown, NSW
    Med J Aust 179:438-40. 2003
  30. ncbi request reprint Making sense of trial results: outcomes and estimation
    Rachel L O'Connell
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 180:128-30. 2004
  31. ncbi request reprint Generalising the results of trials to clinical practice
    J Paul Seale
    Department of Pharmacology, Blackburn Building, University of Sydney, Sydney, NSW 2006, Australia
    Med J Aust 181:558-60. 2004
  32. ncbi request reprint Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis
    David C Burgess
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Level 5, Building F, 88 Mallett Street, Camperdown 2050, Sydney, NSW, Australia
    Eur Heart J 27:2846-57. 2006
    ..Atrial fibrillation (AF) is the most common complication after cardiac surgery. We aimed to evaluate, by meta-analysis, all randomized trials testing interventions for preventing AF...
  33. ncbi request reprint Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial
    Tom G Briffa
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
    Med J Aust 183:450-5. 2005
    ..To estimate the incremental effects on cost and quality of life of cardiac rehabilitation after an acute coronary syndrome...
  34. ncbi request reprint Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002
    Rhana Pike
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450
    Med J Aust 178:316-7. 2003
  35. pmc The relationship between endothelial progenitor cell populations and epicardial and microvascular coronary disease-a cellular, angiographic and physiologic study
    Kim H Chan
    Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia The Heart Research Institute, Sydney, New South Wales, Australia Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
    PLoS ONE 9:e93980. 2014
    ..Moreover, the relationship between different EPC types and the coronary microcirculation is unknown. We therefore investigated the relationship between EPC populations and coronary epicardial and microvascular disease...
  36. ncbi request reprint Allocation concealment and blinding: when ignorance is bliss
    Peta M Forder
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Med J Aust 182:87-9. 2005
  37. ncbi request reprint Baseline data in clinical trials
    David C Burgess
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 179:105-7. 2003
  38. ncbi request reprint Specifying interventions in a clinical trial
    Jackie K Brighton
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 176:281-2. 2002